ICH Considerations General Principles to Address Virus and Vector Shedding (EMEA/CHMP/ICH/449035/2009)

The document "GENERAL PRINCIPLES TO ADDRESS VIRUS AND VECTOR SHEDDING" (EMEA/CHMP/ICH/449035/2009) provides guidelines and principles for addressing the shedding of viruses and vectors in the context of gene therapy or other biotechnological products. Shedding refers to the release of these biological agents from the treated individual into the environment, potentially posing risks to others. Here's a summary of the general principles likely covered in this document:

Definition of Shedding:

The document likely provides a clear definition of what is meant by "shedding" in the context of gene therapy or biotechnological products. Shedding would involve the release of viral vectors or other genetic materials from the treated patient through various routes, such as body fluids, excreta, or skin lesions.

Risk Assessment:

The guidelines outline principles for conducting a comprehensive risk assessment related to shedding. This assessment would consider factors such as the type of vector or virus used, the route of administration, the potential for transmission, and the safety measures in place.

Monitoring and Detection:

It elaborate on how to monitor and detect shedding in patients receiving gene therapy or biotechnological products. This might involve surveillance of body fluids, secretions, or lesions and the use of sensitive assays for detecting viral or vector genetic material.

Communication and Reporting:

Principles for communication and reporting of shedding events are included. This also involve reporting to regulatory authorities, healthcare providers, and patients to ensure appropriate follow-up and safety measures.

Containment and Mitigation:

The document outline strategies for containing shedding and mitigating potential risks to others. This could include recommendations for patient isolation, safe handling of biological materials, and the use of personal protective equipment.

Patient Education:

It provide guidelines on educating patients about shedding risks and appropriate measures to take to prevent potential transmission to others.

Regulatory Compliance:

The document emphasizes the importance of regulatory compliance in addressing shedding concerns. This would include adhering to regulatory requirements and reporting any adverse events or shedding incidents as required by regulatory authorities.

Follow-Up and Long-Term Monitoring:

Guidelines for long-term follow-up and monitoring of patients who have undergone gene therapy or received biotechnological products may be provided. This is essential to assess the persistence of shedding and its potential long-term effects.

Overall, the document likely provides a framework for addressing the complex issue of virus and vector shedding in the context of gene therapy and biotechnological products, with a strong focus on patient safety and public health.

Human Gene Therapy for Neurodegenerative Diseases: FDA Guidance Summary

Neurodegenerative diseases are a diverse group of disorders characterized by the progressive degeneration of the central or peripheral nervous system, and they can have various causes and clinical characteristics. This guidance document is a resource for sponsors on different aspects of product development, preclinical testing, and clinical trial design. It acknowledges the unique challenges and considerations associated with developing GT products for such complex and varied diseases. Below are the key summaries from the guidance. CONSIDERATIONS FOR CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) The considerations for Chemistry, Manufacturing, and Controls (CMC) when developing gene therapy (GT) products for the treatment of neurodegenerative diseases are crucial for ensuring the safety and efficacy of these advanced therapies. Here, we will elaborate on the specific CMC considerations outlined in your text: Route of Administration and Product Volume: Neurodegenerative diseases often r

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product 1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such as ho

SOP on Investigational New Drug (IND) Application and Clinical Investigation Policy

Title: Investigational New Drug (IND) Application and Clinical Investigation Policy Introduction and Purpose: The conduct of clinical investigations (clinical trials) under an FDA-Regulated Investigational New Drug (IND) application involves compliance with a complex set of FDA regulations, requirements, and responsibilities. The FDA holds the IND application sponsor accountable for ensuring compliance with these regulations (21 CFR Part 312, Subpart D). While pharmaceutical companies are typical IND sponsors, individuals, governmental agencies, and academic institutions may also serve as sponsors (21 CFR Part 312.3). This policy serves the following purposes: To assist in determining when an IND is necessary. To provide guidance and resources for individuals conducting clinical investigations, including sponsor-investigators, on obtaining an IND for the investigational drug. To outline the process for compassionate use (expanded access) and emergency use of investigational drugs. Defi

Engineering AAV vectors for enhanced safety profiles

Engineering AAV vectors for enhanced safety profiles involves multiple strategies at both the vector genome and capsid levels. Here is a breakdown of these strategies: Vector Genome Level: Modifying Vector Genome Sequences: Scientists modify AAV vector genomes by adding, mutating, or deleting specific sequences. For example, self-complementary AAV (scAAV) vectors are designed by deleting key signals from the second inverted terminal repeat (ITR), allowing for more efficient genome replication. Codon Optimization: Optimizing the codon usage of the transgene can enhance its expression efficiency. Promoter and PolyA Sequence Selection: Careful selection and manipulation of promoter and polyadenylation (polyA) sequences can influence transgene expression and tissue specificity. Capsid Engineering: Capsid engineering strategies can be categorized into four main categories: Directed Evolution: This approach involves creating capsid mutant libraries using error-prone PCR or introducing pepti

SOP on Safety Events Reporting In Clinical Trials

Title: Standard Operating Procedure for Collection, Evaluation, Documentation, and Reporting of Safety Events in Clinical Trials Introduction and Purpose The assessment of safety events and the accurate reporting of these events are fundamental aspects of conducting clinical trials. These processes are crucial for ensuring the safety and well-being of research participants. This Standard Operating Procedure (SOP) outlines the procedures for collecting, evaluating, documenting, and reporting safety events, including Adverse Events (AE), Serious Adverse Events (SAE), Unanticipated Problems (UP), and other relevant safety events during the course of a clinical trial. The Principal Investigator (PI) holds the primary responsibility for the overall conduct of the trial, safeguarding the rights, safety, and welfare of study subjects, and ensuring that the investigation adheres to the protocol, Good Clinical Practice (GCP), Institutional Review Board (IRB), Food and Drug Administration (FDA),

Cell And Gene Therapy: Research, Development & Regulatory Guidance

Search This Blog